Plaintiff: Xlear Inc. and Jones Bozeman Family Limited Partnership (JBFLP)
Defendant: Himalayan International Institute of Yoga Science and Philosophy of the USA
Case Number: 2:13-cv-00230
Case Type: Patent Infringement
Court: Utah District Court
Patent Number
Current Assignee[1]
|
Issue Date
|
Expiration Date[2]
|
Title
|
US6054143
Jones Bozeman Family Limited Partnership
|
Apr 25, 2000
|
Dec 23, 2018
|
Xylitol delivery
|
US6258372
Jones Bozeman Family Limited Partnership
|
Jul 10, 2001
|
Dec 23, 2018
|
Xylitol nose spray
|
Source: MaxVal’s Assignment Database.
As per complaint:
Xlear is the exclusive licensee of the ‘143 and ‘372 patents. It is said that Dr. Jones, the inventor of the ‘143 and ‘372 patents, began his research on the effects of Xylitol in response to his granddaughter’s frequently recurring earaches. He recognized that many infections causing bacteria enter through the nose due to which upper respiratory infections including Otitis media, asthma, sinusitis and allergies are caused. Dr. Jones discovered that Xylitol administered through the nose would have a preventative effect on a variety of upper respiratory infections. Xlear nasal washes and sprays incorporating the patented technology were marketed.
Xlear alleges that defendant via their website (www.himalayaninstitute.org) sells nasal sprays containing Xylitol with the same ingredients as claimed in the patented technology and thus infringes the above said patents.
Other cases filed:
The cases filed by JBFLP are as follows:
- Prohealth (2:08-cv-00629)
- Nutribiotic (2:07-cv-00675)
- Now Health Group (2:2006cv00283)
Has this patent been litigated? Use our free tool or download our free Android app on Google Play.
[1] MaxVal offers Patent Assignment Alert service where subscribers receive email alerts when assignments relating to target applications, patents or entities of interest are recorded.
[2] Expected expiration date. Patent Term Estimator is a free web-based tool that automatically calculates patent terms and expiration dates for U.S. utility patents.
No comments:
Post a Comment